Get the Stockscreener App
10.39
1.56%
0.16
Daxor Corporation stock is traded at $10.39, with a volume of 14,582.
It is up +1.56% in the last 24 hours and down -14.27% over the past month.
Daxor Corporation, a medical device company, provides biotechnology and cryobanking services in the United States. The company offers BVA-100 Blood Volume Analyzer, an instrument that measures blood volume in human body. BVA-100 Blood Volume Analyzer is used to diagnose and treat patients in various medical and surgical conditions, including congestive heart failure, critical care medicine and intensive care unit medicine, hypertension, syncope, pre-operative blood screening for hidden anemia, anemia in cancer patients, kidney failure, and hyponatremia. It also provides semen banking, blood storage, andrology, and general lab testing services. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was founded in 1970 and is headquartered in New York, New York.
See More
Previous Close:
$10.23
Open:
$10.365
24h Volume:
14,582
Relative Volume:
1.74
Market Cap:
$60.54M
Revenue:
$503.40K
Net Income/Loss:
$9.17M
P/E Ratio:
5.7375
EPS:
1.8109
Net Cash Flow:
$-604.40K
1W Performance:
-6.48%
1M Performance:
-14.27%
6M Performance:
-13.29%
1Y Performance:
+26.94%
1-Day Range:
$10.29
$10.50
1-Week Range:
$10.13
$11.50
52-Week Range:
$7.10
$14.76
Daxor Corporation Stock (DXR) Company Profile
Name
Daxor Corporation
Sector
Industry
Phone
212-330-8500
Address
Empire State Building, Suite 7120 350 Fifth Avenue, New York, NY
Compare DXR vs ISRG, BDX, ALC, MDLN, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DXR
Daxor Corporation
|
10.39 | 60.54M | 503.40K | 9.17M | -604.40K | 1.8109 |
ISRG
Intuitive Surgical Inc
|
469.98 | 166.92B | 10.06B | 2.88B | 2.49B | 7.876 |
BDX
Becton Dickinson Co
|
158.27 | 45.02B | 21.92B | 1.76B | 2.63B | 6.1223 |
ALC
Alcon Inc
|
75.26 | 36.68B | 10.40B | 980.00M | 1.61B | 1.9749 |
MDLN
Medline Inc
|
42.67 | 34.63B | 28.43B | 1.16B | 1.26B | 1.4457 |
RMD
Resmed Inc
|
226.31 | 32.97B | 5.40B | 1.49B | 1.78B | 10.12 |
Daxor Corporation Stock (DXR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-16-19 | Initiated | Ascendiant Capital Markets | Buy |
Daxor Corporation Stock (DXR) Latest News
Daxor Corporation (NASDAQ:DXR) Short Interest Update - MarketBeat
Daxor (DXR) chief medical officer Jefferies acquires shares worth $0 - Investing.com
Daxor (DXR) chief medical officer Jefferies acquires shares worth $0 By Investing.com - Investing.com Australia
Daxor (DXR) CMO boosts stake with 5,941-share equity grant - Stock Titan
Macro Review: What is the long term forecast for Daxor Corporation stockEarnings Trend Report & Daily Price Action Insights - baoquankhu1.vn
Institution Moves: What is the earnings history of Daxor CorporationChart Signals & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Daxor Corporation to Showcase Next-Generation Portable - GlobeNewswire
Daxor to showcase next-gen portable BVA at ACC.26 session - TipRanks
Daxor (DXR) Showcases Innovative Blood Volume Analyzer at Major Cardiology Event - GuruFocus
Daxor Corporation Showcases Next-Generation Portable Blood Volume Analyzer At ACC.26 - marketscreener.com
Daxor Corporation to Showcase Next-Generation Portable Blood Volume Analyzer at ACC.26; Highlighting Clinical Outcomes and Reduced Readmissions - marketscreener.com
Blood volume test cut heart failure readmissions 56% in studies - Stock Titan
[N-CEN] DAXOR CORP SEC Filing - Stock Titan
Daxor Details Portable FDA-Cleared Blood Volume Analyzer, 'Razor-and-Blades' Kit Growth at iAccess Alpha - MarketBeat
DXR: Direct blood volume analysis drives improved outcomes and rapid revenue growth in a vast market - TradingView
Daxor (DXR) Unveils Portable Blood Volume Analyzer at Critical C - GuruFocus
Daxor Corporation Showcases New Portable Blood Volume Analyzer - marketscreener.com
Daxor to debut portable blood volume analyzer at SCCM Critical Care Congress - TipRanks
ICU blood volume test linked to 66% fewer deaths goes portable - Stock Titan
Daxor Corporation to Participate in the iAccess Virtual Alpha Best Ideas Spring Investment Conference 2026 - GlobeNewswire
Virtual investor conference to feature Daxor CEO’s 30-minute briefing - Stock Titan
Market Overview: Will Murano Global Investments Plc Equity Warrant benefit from rate cuts2026 Top Gainers & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
What analyst consensus says on Daxor Corporation stockExit Point & Fast Moving Trade Plans - Naître et grandir
Layoff Watch: Is Daxor Corporation a turnaround storyGap Up & Safe Entry Trade Reports - baoquankhu1.vn
Daxor (NYSEAMERICAN:DXR) Share Price Passes Below 200-Day Moving AverageHere's What Happened - MarketBeat
European Stocks Set for Mixed Opening Amid Geopolitical Tensions - Intellectia AI
DXR SEC FilingsDAXOR CORP 10-K, 10-Q, 8-K Forms - Stock Titan
Daxor Corporation Reports 2025 Fiscal Year Results, Operating Revenue Up 45%, Net Asset Value Rises to $9.07 per Share - marketscreener.com
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders - Bitget
Daxor reports 45% revenue growth, plans regulatory shift - Investing.com
Daxor Corporation CEO and President Michael Feldschuh provides corporate update in letter to shareholders - marketscreener.com
Daxor (DXR) Records Strong Growth and Regulatory Changes in 2025 - GuruFocus
Daxor issues update in Letter to Shareholders - TipRanks
Daxor (DXR) Secures FDA Clearance for Advanced Blood Volume Anal - GuruFocus
Daxor Corporation CEO And President Michael Feldschuh Provides Corporate Update In Letter To Shareholders - TradingView
7-pound blood volume analyzer wins FDA clearance, gains hospital users - Stock Titan
Daxor Corporation Reports 2025 Fiscal Year Results: Operating Revenue Up 45%, Net Asset Value Rises to $9.07 Per Share - marketscreener.com
Daxor Corporation Reports 2025 Fiscal Year Results: - GlobeNewswire
DXR Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
FDA‑cleared BVA boosts momentum; Daxor (NASDAQ: DXR) posts NAV $9.07 and $46M operating valuation - Stock Titan
Daxor Corporation Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Short Interest in Daxor Corporation (NASDAQ:DXR) Decreases By 44.0% - MarketBeat
Daxor Corporation (DXR) Competitors - Meyka
Daxor (NASDAQ:DXR) vs. Addus HomeCare (NASDAQ:ADUS) Financial Survey - Defense World
EBIT per share of Daxor Corporation – NASDAQ:DXR - TradingView
Daxor (NYSEAMERICAN:DXR) Share Price Crosses Below Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Daxor continues strategic expansion, opens new BVA program in Tennessee - TipRanks
Analysts Offer Insights on Healthcare Companies: Daxor (DXR) and HealthStream (HSTM) - The Globe and Mail
Daxor (DXR) Expands BVA Program to Southern Middle Tennessee - GuruFocus
Daxor Scales Outpatient Presence; Launches BVA Diagnostic Program in Tennessee - The Manila Times
Gainers Report: Will LightPath Technologies Inc benefit from government policy2025 Key Lessons & Real-Time Stock Price Movement Reports - baoquankhu1.vn
Daxor Corporation Stock (DXR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.95%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):